Reimbursement Processes for Keytruda in Israel, UK, and Australia

By Staff Writer

February 26, 2023

Introduction:

New cancer therapies, such as pembrolizumab, come with high costs, presenting a unique challenge for resource allocation decisions across nations and healthcare systems. Developed countries with national universal health insurance coverage have established different methods. Time to Reimbursement of Pembrolizumab and other oncology treatment are of utmost importance for high level of care. These methods orderly and transparently assess new technologies before adding them to their list of reimbursed services. This process, known as the “fourth hurdle”, is a stage after a country registers the technology. Here, the new technology must show value for money. It also needs to prove its effectiveness and safety before it can qualify for reimbursement from public funds. 

International Approaches:

This research utilises a comparative approach, examining the reimbursement process for pembrolizumab, a cancer treatment drug, in three different healthcare systems: The National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK), the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the National Advisory Committee for the Basket of Health Services in Israel. Data were collected from publicly available websites and relevant literature.

Time to Reimbursement of Pembrolizumab:

The research found significant differences in time to reimbursement in these countries, with Israel approving two conditions earlier than the UK and Australia. This paper suggests that unique healthcare policies and systems in these countries could account for these differences.

Conclusion:

The study concludes by suggesting the need for a debate on how to encourage earlier access to necessary and life-saving cancer treatments in countries where the reimbursement process is longer. The most important challenge was budget limitations among many factors that are taken into account in the reimbursement process, and length of time from registration to reimbursement in the public health system of each country.

Reference url

Recent Posts

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

Trump science publishing critique
   

Trump Science Publishing Critique: Analyzing Political Interference and Methodological Issues

🔍 Is political influence undermining the integrity of scientific publishing?

In his thought-provoking article, Kamran Abbasi critiques the Trump administration’s attempts to shape medical literature, revealing serious methodological flaws and biases that could jeopardize scientific progress. This analysis emphasizes the need for transparency and rigor in research to ensure that political pressures do not compromise the quality of scientific discourse.

Curious to learn more about the implications for healthcare and the future of scientific publishing? Click to read the full article!

#SyenzaNews #HealthEconomics #HealthcarePolicy

NHI Bill court ruling
      

South Africa NHI Bill Court Ruling Calls for Scrutiny

🔍 What does a recent court ruling mean for South Africa’s healthcare system?

This pivotal decision from the Gauteng High Court mandates President Cyril Ramaphosa to justify his signing of the National Health Insurance Bill, opening the door for judicial review of executive decisions in healthcare legislation. As the implications of this ruling unfold, it reflects a significant check on executive power, particularly in contentious policy areas.

Curious to learn more about the potential impact on the NHI Act and South Africa’s healthcare future? Dive into the full article for comprehensive insights!

#SyenzaNews #HealthcarePolicy #HealthTech #Governance

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.